Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Merck Patent GmbH | 163 |
| 2 | BASF SE | 9 |
| 3 | Baxter Biotech Technology SARL | 7 |
| 4 | Global Blood Therapeutics Inc | 7 |
| 5 | University of Toronto Innovations Foundation | 7 |
| 6 | Exact Sciences Corp | 6 |
| 7 | University of California, San Diego | 6 |
| 8 | Columbia University | 5 |
| 9 | Searete LLC | 5 |
| 10 | University of Minnesota System | 5 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 398 |
| 2 | A61P | Therapeutic activity (drug indications) | 233 |
| 3 | A61Q | Cosmetics, personal care | 194 |
| 4 | C07K | Peptides | 101 |
| 5 | C07D | Heterocyclic compounds | 79 |
| 6 | A01N | Preservation of bodies; biocides; pest repellents | 71 |
| 7 | C07C | Acyclic and carbocyclic compounds | 52 |
| 8 | C12N | Microorganisms, enzymes | 44 |
| 9 | A61M | Devices for introducing media into the body | 36 |
| 10 | A61L | Sterilising / disinfecting materials | 34 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionMost-cited patents
Patents ranked by forward citations reveal the foundational inventions the field continues to build on.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| METHOD AND COMPOSITION FOR DETERMINING D-GLYCEROALDEHYDE-3-PHOSPHORIC ACID, INOGANIC PHOSPHORUS, OR 1,3-DIPHOSPHOGLYCERIC ACID IN HIGH SENSITIVITY | 1992 | Asahi Chemical Industry Co Ltd | 7 |
| A FORMULATION AND A PROCESS FOR REDUCING THE DETERIORATION OF RBCs OF BLOOD DURING STORAGE WITH PARTICULAR REFERENCE TO DECREASE IN THE LEVEL OF 2,3 DIPHOSPHOGLYCERATE | 2004 | CHANDRASEKHAR, BALAGOPAL | 6 |
| Cosmetic and dermatological formulations using cyclic 2,4-diphosphoglycerate (cDGP) and / or derivatives | 2004 | ビトプ アクチェンゲゼルシャフト フューア ビオテヒニシェ オプティミールング | 4 |
| Application of phthalide compound in preparing medicine for treating Alzheimer disease and abnormal metabolism of 2, 3-diphosphoglycerate | 2017 | SUN YAT-SEN UNIVERSITY | 1 |
| Use of cyclic 2,4-diphosphoglycerate (cDGP) and / or derivatives in cosmetic and dermatological formulations | 2002 | BITOP GESELLSCHAFT FUER BIOTECHNISCHE OPTIMIERUNG MBH | 1 |
Where research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Hemoglobin structure and function | 12 |
| 2 | Hemoglobinopathies and Related Disorders | 7 |
| 3 | Renal function and acid-base balance | 4 |
| 4 | Amino Acid Enzymes and Metabolism | 3 |
| 5 | Erythrocyte Function and Pathophysiology | 3 |
| 6 | Dialysis and Renal Disease Management | 2 |
| 7 | Enzyme Structure and Function | 2 |
| 8 | Neonatal Health and Biochemistry | 2 |
| 9 | Advanced MRI Techniques and Applications | 1 |
| 10 | Blood disorders and treatments | 1 |
Technology trend analysis
Cypris uses AI to connect emerging research themes to IP activity, commercialization signals, and underexplored opportunity areas.
See Cypris in actionWho's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Bruno Giardina | University of Rome Tor Vergata | 17 |
| 2 | C. R. Valeri | United States Naval Research Laboratory | 10 |
| 3 | Claire Poyart | Bicêtre Hospital | 10 |
| 4 | Angelo D’Alessandro | University of Colorado Denver | 9 |
| 5 | Alvarez-Sala Jl | Universidad Complutense de Madrid | 8 |
| 6 | A. Frans | Cliniques Universitaires Saint-Luc | 7 |
| 7 | Claes F. Högman | Uppsala University Hospital | 7 |
| 8 | B. Bohn | Inserm | 6 |
| 9 | Josep Carreras | Universitat de Barcelona | 6 |
| 10 | Roy E. Weber | Aarhus University | 6 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Operation Everest II: oxygen transport during exercise at extreme simulated altitude | 1988 | 417 | Chronic Obstructive Pulmonary Disease (COPD) Research |
| Respiratory Function of Hemoglobin | 1998 | 299 | Neonatal Health and Biochemistry |
| A Randomized Study of Phosphate Therapy in the Treatment of Diabetic Ketoacidosis* | 1983 | 246 | Pancreatic function and diabetes |
| Sphingosine-1-phosphate promotes erythrocyte glycolysis and oxygen release for adaptation to high-altitude hypoxia | 2016 | 213 | Autophagy in Disease and Therapy |
| The Effect of Sepsis on the Erythrocyte | 2017 | 199 | Blood properties and coagulation |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular composition and structure of 2,3-Diphosphoglyceric Acid?
Which organizations hold the most patents related to 2,3-Diphosphoglyceric Acid?
What are the primary research topics associated with 2,3-Diphosphoglyceric Acid in published literature?
Who are the leading researchers publishing on 2,3-Diphosphoglyceric Acid?
What is the patent classification landscape for 2,3-Diphosphoglyceric Acid?